What is Sub-Q Bionics?
Sub-Q Bionics is a specialized medical technology firm focused on the development of an implantable lymphatic drainage system. The company addresses the critical needs of cancer survivors suffering from lymphedema, a debilitating condition characterized by chronic swelling and mobility impairment. By utilizing an implantable device that operates beneath the skin to facilitate lymphatic circulation, the company provides a sophisticated alternative to traditional, often cumbersome, external management therapies.
Headquartered in Stillwater, Minnesota, the company operates at the intersection of bioengineering and clinical care. Its core technology is designed to mitigate the discomfort and physical limitations associated with lymphatic fluid accumulation, representing a significant advancement in patient-centric medical hardware. The firm's strategic focus remains on improving quality of life through durable, internal mechanical solutions that integrate seamlessly into the patient's physiology.
How much funding has Sub-Q Bionics raised?
Sub-Q Bionics has raised a total of $1.5M across 1 funding round:
Angel/Pre-Seed
$1.5M
Angel/Pre-Seed (2026): $1.5M with participation from Mayo Clinic and Yeda Research and Development
Key Investors in Sub-Q Bionics
Mayo Clinic
A nonprofit global healthcare leader specializing in integrated clinical practice, medical research, and education, known for its multidisciplinary approach to complex health conditions.
Yeda Research and Development
The commercial arm of the Weizmann Institute of Science, focused on translating academic research into market-ready technologies across the biotech and medical device sectors.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Sub-Q Bionics?
Looking ahead, Sub-Q Bionics is expected to utilize its recent financing to scale its research and development operations and initiate expanded clinical trials. The company's roadmap likely includes optimizing the device's biocompatibility and long-term efficacy, which are essential milestones for securing future regulatory approvals. As the firm continues to mature, it will likely seek further strategic partnerships to facilitate manufacturing and eventual commercial distribution.
The involvement of high-caliber research institutions suggests that the company will maintain a strong emphasis on evidence-based medicine. Future growth will be contingent upon the successful demonstration of the device's performance in diverse patient populations, potentially opening doors for broader applications in chronic disease management. Investors will be closely monitoring the company's progress as it moves toward the next phase of its clinical lifecycle.
